NCT01749137View on ClinicalTrials.gov

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 14, 2013

Primary Completion Date

September 28, 2013

Study Completion Date

September 28, 2013

Conditions
Overweight
Interventions
DRUG

Setmelanotide

Daily subcutaneous infusion

DRUG

Placebo

Daily subcutaneous infusion

Trial Locations (6)

Unknown

Miami

Lexington

Rochester

Raleigh

Dallas

Renton

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT01749137 - Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | Biotech Hunter | Biotech Hunter